TABLE 4

OS

Univariate analysisMultivariate analysis
ParameterHRPHRP
Sex1.22 (0.47–3.17)0.68——
Age1.03 (0.99–1.07)0.1003——
ECOG status2.73 (0.88–8.44)0.081.85 (0.47–7.24)0.38
Primary tumor treatment (surgery vs. proton therapy)1.22 (0.39–3.84)0.74——
Time between eye tumor diagnosis and metastasis0.99 (0.97–1.00)0.12——
Time between metastasis diagnosis and SIRT0.89 (0.50–1.61)0.72——
Largest lesion (cm)1.30 (1.08–1.57)0.0051.22 (0.98–1.53)0.08
Estimated number of lesions1.28 (0.48–3.45)0.62——
Metastasis distribution (unilobar/bilobar)1.41 (0.32–6.22)0.65——
Baseline SUVmax1.02 (0.91–1.15)0.72——
Extrahepatic metastases before SIRT1.21 (0.34–4.29)0.77——
90Y-microspheres (SIR-Spheres vs. TheraSphere)0.75 (1.34–2.12)0.34——
Treated tumor volume (cm3)1.0008 (1.0001–1.002)0.021.002 (1.0004–1.003)0.007
Liver treated (lobar vs. whole)0.72 (0.25–2.09)0.55——
Liver treated (whole in 1 session, whole in multiple sessions, lobar)0.91 (1.10–1.43)0.54——
Number of SIRTs per patient1.001 (0.42–2.37)0.99——
Mean of all SIRT session activity administered per patient (GBq)2.54 (0.96–6.73)0.06—*—
Sum of all SIRT session activity administered per patient (GBq)1.19 (0.77–1.86)0.42——
Mean dose to healthy liver (Gy)0.98 (0.95–1.01)0.18——
Mean dose to tumor (Gy)0.99 (0.98–1.01)0.56——
Tumor-to-liver uptake ratio1.11 (0.89–1.38)0.36——
Pulmonary shunt fraction (%)0.43 (0.15–1.21)0.11——
Post-SIRT systemic therapies0.33 (0.12–0.86)0.020.04 (0.006–0.24)0.0005
Post-SIRT locoregional therapies0.21 (0.07–0.62)0.0050.204 (0.04–0.94)0.04
Extrahepatic metastasis after SIRT0.98 (0.28–3.48)0.98——
Highest complication grade (CTCAE)1.37 (0.86–2.18)0.19——

  • ↵* Omitted from multivariate analysis as it is highly correlated with treated tumor volume.

  • CTCAE = Common Terminology Criteria for Adverse Events.

  • Data in parentheses are 95%CI.